ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1634

A Lexicon of Signs and Symptoms of Giant Cell Arteritis: An International Expert Consensus
Abstract Number: 2593

A Long-term Synovial Tissue 3D Model Incorporating Fibroblasts, Macrophages, Endothelial Cells, and Other Immune Cells Such as Innate Lymphoid Cells Enables Animal Model-Independent Rheumatoid Arthritis Research
Abstract Number: 0886

A Longitudinal Cohort Study Uncovers Plasma Protein Biomarkers Predating Clinical Onset and Treatment Response of Rheumatoid Arthritis
Abstract Number: 2099

A Longitudinal Study of Infrapatellar Fat Pad Morphologies as Predictive Markersin Knee Osteoarthritis
Abstract Number: 0492

A Machine Learning Model for the Early Identification of Rheumatoid Arthritis: Development and Validation
Abstract Number: 0760

A Macrophage-smooth Muscle Cell Axis Influences Vascular Remodeling Through Activation of the EGFR Pathway in Giant Cell Arteritis
Abstract Number: 1128

A Meta-Analysis of Statin Efficacy in Controlling Disease Activity in Psoriasis
Abstract Number: 2096

A Model Based on Clinical and Molecular Data Predcits the Risk of Total Joint Replacement Progression in Knee OA Patients from the OAI
Abstract Number: 2556

A Multi-center Study of Associations Between Neighborhood-Level Child Opportunity, Initial Disease Severity and Acute Care Utilization Among Children with SLE
Abstract Number: 0774

A Multicenter, Randomized, Controlled Trial to Evaluate the Effects of Low-dose Glucocorticoids Compared to Stopping Glucocorticoids to Maintain Remission of Granulomatosis with Polyangiitis: The TAPIR Trial
Abstract Number: 0174

A Nationwide Analysis of Gender and Racial Disparities in Patients with Systemic Sclerosis and Acute Coronary Syndrome
Abstract Number: 2589

A Nationwide Analysis of Risk of Acute Coronary Syndrome in RA Patients with Interstitial Lung Disease
Abstract Number: 1291

A Needs Assessment to Inform the Design of a Musculoskeletal Ultrasound Curriculum for Internal Medicine Residents
Abstract Number: 0092

A New Generation Mesenchymal Stromal Cell (MSC)-based Cell Therapy Using Design of Experiments Halts Pristane Induced Glomerulosclerosis
Abstract Number: 2267

A Novel Blood-based Assay That Predicts Clinical Response to TNFα Inhibitors or Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].